South San Francisco, CA, United States
Healthcare, It, Research, Post Doc, Pharmaceutical, Biotech
We have a postdoctoral position open to study adult stem cells, differentiation and cell fate control in tissue maintenance, regeneration and cancer.
Notch signaling has long been appreciated as a key arbiter of cell fate determination, directing lineage decisions during development and tissue repair. A previous postdoctoral discovery, however, revealed a new paradigm, one in which Notch controls cellular transdifferentiation in the adult lung epithelium. Recent work strongly suggests that this paradigm extends to other tissues and, excitingly, may enable therapeutic targeting of cancers subtypes that reflect a transformed version of a normal adult progenitor cell. We are currently testing this hypothesis in the liver, focusing on liver regeneration and liver cancers that exquisitely depend on Notch. We suspect that the lessons learned here will apply to other tissues and tumors, particularly in the skin and ovaries. The next generation of postdoctoral research will not only impact these basic scientific questions and therapeutic hypotheses but also may yield important general insights into adult stem cell function, damage responses and regeneration.
For information about other areas of research and the lab of Chris Siebel, visit: https://www.gene.com/scientists/our-scientists/chris-siebel
For information about the Genentech Postdoctoral Program, visit: http://www.gene.com/careers/academic-programs/postdocs
Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice
Vedran Radojcic; Katelyn Paz; Jooho Chung; Jing Du; Eric Perkey; Ryan Flynn; Sanja Ivcevic; Michael Zaiken; Ann Friedman; Minhong Yan; Maria A. Pletneva; Stefanie Sarantopoulos; Christian W. Siebel; Bruce R. Blazar; Ivan Maillard
Constitutive NOTCH3 signaling promotes basal breast cancer growth.
Cancer Research, 2017
Lisa Choy; Thijs Hagenbeek; Margaret Solon; Dorothy French; David Finkle; Amy Shelton; Rayna Venook; Matthew Brauer; Chris Siebel
Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung
Daniel Lafkas; Amy Shelton; Cecilia Chiu; Gladys Boenig; Yongmei Chen; Scott Stawicki; Christian Siltanen; Mike Reichelt; Meijuan Zhou; Xiumin Wu; Jeff Eastham Anderson; Heather Moore; Meron Roose-Girma; Yvonne Chinn; Julie Q. Hang; Soren Warming; Jackson Egen; Wyne Lee; Cary Austin; Yan Wu; Jian Payandeh; John B. Lowe (Path); Chris Siebel
Therapeutic antibody targeting of individual Notch receptors
Yan Wu; Carol Cain-Hom; Lisa Choy; Thijs Hagenbeek; Gladys P. De Leon; Yongmei Chen; David Finkle; Rayna Venook; Xiumin Wu; John Brady; Dorreyah Schahin-Reed; Graham Dow; Amy Shelton; Scott Stawicki; Ryan Watts; Jeff Zhang; Robert Choy; Peter Howard; Lisa Kadyk; Minhong Yan; Jiping Zha; Chris Callahan; Sarah Hymowitz; Chris Siebel
Candidates should have a doctoral degree and at least one first-author paper published or accepted in a peer-reviewed journal, with technical expertise in molecular and cellular biology. Experience working with animal models, especially mice, is desirable, as is knowledge of developmental signaling pathways, stem cell regulation and biochemistry.
Who We Are
A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 40 years, using human genetic information to develop novel medicines for serious and life-threatening diseases. Genentech has multiple therapies on the market for cancer & other serious illnesses. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
The next step is yours. To apply today, click on the Apply online button.
Genentech is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. For more information about equal employment opportunity, visit our Genentech Careers page
Website : http://www.gene.com
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.